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Abstract: Characterization of multiple antibody epitopes has revealed the necessity of specific
groups of amino acid residues for reactivity. This applies to the majority of antibody–antigen
interactions, where especially charged and hydrophilic amino acids have been reported to be
essential for antibody reactivity. This study describes thorough characterization of glutamic acid
decarboxylase (GAD) 65 antigenic epitopes, an immunodominant autoantigen in type 1 diabetes (T1D).
As linear epitopes are sparsely described for GAD65 in T1D, we aimed to identify and thoroughly
characterize two GAD65 antibodies using immunoassays. A monoclonal antibody recognized an
epitope in the N-terminal domain of GAD65, 8FWSFGSE14, whereas a polyclonal antibody recognized
two continuous epitopes in the C-terminal domain, corresponding to amino acids 514RTLED518
and 549PLGDKVNF556. Hydrophobic amino acids were essential for antibody reactivity, which was
verified by competitive inhibition assays. Moreover, the epitopes were located in flexible linker regions
and turn structures. These findings confirm the versatile nature of antibody–antigen interactions and
describe potential continuous epitopes related to T1D, which predominantly have been proposed to
be of discontinuous nature.
Keywords: antibody; antigen; glutamate decarboxylase; peptides; type 1 diabetes
1. Introduction
The majority of epitopes currently analyzed are discontinuous [1]. It has been estimated that
70–90% of all epitopes are discontinuous. Characterization of discontinuous epitopes is rather
complicated compared to continuous epitopes, also referred to as linear epitopes. Nevertheless, as the
epitopes are composed of similar amino acids (aas), results obtained using continuous epitopes are
directly related to discontinuous models.
The majority of epitopes are composed of 8–12 aas [1–6]. Except from antibodies recognizing
modified epitopes, are epitopes seldom shorter than 6 aas, as antibody-antigen interactions depend
on several aas for a stable interaction [7–9]. Secondary structures and structure flexibility are central
elements for a stable antibody-antigen interaction. Thus are flexible regions, loops and turns, but also
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occasionally α-helices favored epitope structures [1,10–13]. Epitopes primarily located on the surface
of proteins are often favored due to an increased antibody accessibility [1,4].
Epitope structures are often rich in hydrophilic and charged aas, especially Arg, Asp and Glu,
and with a lower ratio of aliphatic hydrophobic aas, although several epitopes have been described
that depend on hydrophobic aas for stable interactions [1,2,13–16]. Moreover, the aas Tyr and Trp
have been found to be overrepresented in epitopes as well [1]. These findings have been supported by
previous studies, claiming that Tyr, Trp and charged residues generally are preferred in protein–protein
interfaces due to their capability to form a multitude of interactions [3,6,13,14,17–20]. Aas, such as the
hydrophobic aas Pro and Gly, are often found in epitopes as well, as these aas often are represented
in turns and flexible regions [1,6,13]. Besides individual aa preferences, specific aa pairs have been
observed in epitopes, suggesting that some aa pairs, e.g., Tyr:Tyr, Cys:Pro, Asn:Tyr. Asp:Pro, Arg:Tyr,
Asn:Tyr and His:Tyr, work cooperatively in mediating antibody binding [1].
The number of aas essential for antibody reactivity varies depending on the type of
antibody–antigen interaction. For example, an interaction with a high affinity may experience a
1000-fold reduction in antibody reactivity when substituting an essential aa, whereas a neighbour
aa may be substituted without interfering with the affinity, although they are a central part of an
epitope structure [6,7,9,20]. This may apply to the fact that some aas contribute with a specific
side chain contribution (e.g., ionic bond or hydrophobic interaction) for a stable antibody–antigen
interaction, whereas other aas contribute with backbone interactions (hydrogen bonds), which in
theory can be contributed by any aa. The substitution of a central aa, which contributes with backbone
interactions does not alter the secondary structure of the epitope unless its side chain interferes with
other interactions [8,9,13].
Several assays for epitope characterization exist, but one of the most straightforward methods
is to use immunoassays [5,7,10,13,19]. In these assays, usually a protein or peptide is coupled or
coated onto a solid surface, which is recognized by a primary antibody. Bound antibodies are usually
determined using labelled secondary antibodies. This approach has been used with great success
for characterization of several linear epitopes [2,3,10,13,19]. When using methods such as X-ray
crystallography, significant amounts of data are obtained at the atomic level in relation to specific
interactions between the individual aas of the antibody and antigen, nevertheless, this type of epitope
characterization is rather time consuming and requires a notable amount of material for the generation
of suitable crystals [21,22].
Knowledge of epitopes related to the glutamic acid decarboxylase (GAD) protein is sparse. GAD is
a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the conversion of L-glutamic acid to
the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and is among others expressed in the
pancreatic β-cells [23–25]. In mammals, two isoforms of GAD exist, GAD67 and GAD65, based on
their molecular weight. The isoforms show a general overall sequence similarity, with the middle
and C-terminal domains having 74% identity, but differing (25% identity) in the N-terminal domain,
mainly in the first 100 aas [23,24]. The two isoforms differ in their enzyme activity. GAD67 is located in
the cytoplasm, is constitutively active, and provides for the basal production of GABA, whereas GAD65
is present in synaptic vesicles (besides the pancreatic β-cells) and undergoes auto-inactivation during
enzyme activity, which occurs in the cell providing for a pulse in production under circumstances that
demand a rapid surge of GABA synthesis and release [23–26].
The two isoforms are divided into three functional domains, an amino-terminal domain, a middle
domain where the catalytic site resides (PLP-binding domain), and a carboxy-terminal domain. Roughly,
antibodies to GAD67 are primarily associated with stiff-person syndrome (SPS) and autoimmune
polyendocrine syndrome type 1, whereas GAD65 is a dominant autoantigen in type 1 diabetes
(T1D) [2,24–29].
Epitope specificity in GAD-related neurological diseases has been examined only for SPS,
indicating that the antibodies are directed against continuous GAD epitopes in all 3 domains,
but predominantly against the catalytic region [30]. In contrast, GAD epitopes related to T1D
Int. J. Mol. Sci. 2019, 20, 2909 3 of 13
are often directed to discontinuous GAD epitopes located in the middle and C-terminal domains [31].
Most T1D sera contain two distinct GAD antibody specificities, one of which targets an epitope region
in the middle-third of GAD65 (aas 221–359) and one of which targets the carboxy-third of GAD65
(aas 453–569) [31,32]. Only few epitopes in the N-terminal region have been described.
As epitope characterization of discontinuous epitopes can be rather challenging, no in depth
characterization of GAD65 epitopes has been conducted until now. A single study describes reactivity
to continuous GAD65 epitopes in patients with slowly progressive T1D. Here, GAD65 antibodies
reacted specifically with an N-terminal linear epitope in the membrane-anchoring domain between aas
17–51 [33]. Furthermore, a conformational epitope between aas 244–360 was identified in a group of
young individuals with acute onset T1D [33]. However, no study currently has described specific aa
contributions to the antigen–antibody interaction between GAD65 and respective autoantibodies.
In this study, three continuous GAD65 epitopes were thoroughly characterized with emphasis
on essential aas necessary for antibody recognition and aa side chain functionality in order to obtain
further knowledge of the specific interactions between GAD65 and autoantibodies related to T1D.
2. Results
2.1. Screening of Overlapping Peptides Identifying Antigenic Regions
To identify potential epitopes of two GAD65 antibodies, screening of overlapping resin-bound
peptides covering the respective immunogens (aa 4–22 for the mAb GAD65 and aa 353–585 for the
pAb GAD65) was conducted by modified enzyme-linked immunosorbent assay (ELISA).
Figure 1a illustrates the reactivity of the mAb to peptides originating from the N-terminus of
GAD65. Significant antibody reactivity was found to peptide 1 (aa 1–20, MASPGSGFWSFGSEDGSGDS).
No antibody reactivity was found to peptide 2 (aa 10–30, FGSEDGSGDSENPGTARAWC) or 3 (aa 20–40,
ENPGTARAWCQVAQKFTGGI). These findings indicate that the epitope of the mAb is located in the
first 10 aas of the peptide or within the common overlap of peptides 1 and 2 (approximately aas 5–15).
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Figure 1. Reactivity of antibodies to GAD65 peptides analysed by modified enzyme-linked 
immunosorbent assay using resin-bound peptides. (a) Reactivity of the mAb GAD65 to peptides 1–3. 
Resin without peptides was used for background determination and subtracted. Peptide 1: aa 1–20, 
peptide 2: aa 10–30, peptide 3: aa 20–40. Peptide 3 was used as control peptide; (b) reactivity of the 
pAb GAD65 to overlapping 20mer peptides covering aas 353–585. Resin without peptides was used 
for background determination and subtracted; (c) reactivity of irrelevant antibody to overlapping 
peptides covering aas 353–585. 
2.2. Screening of N-Terminally and C-Terminally Truncated Peptides  
To identify the terminal epitope borders of the GAD antibodies, N- and C-terminal truncated 
resin-bound peptides were screened for antibody reactivity by modified ELISA. Peptides 1 
(MASPGSGFWSFGSEDGSGDS), 52 (PSLRTLEDNEERMSRLSKVA) and 55 
(GTTMVSYQPLGDKVNFFRMV) were used as templates for the generation of truncated peptides.  
Figure 2 represents GAD65 antibody reactivity to the terminally truncated peptides. For the 
mAb, the N-terminal aa Phe (aa 8) and the C-terminal aa Glu (aa 14) were essential for antibody 
reactivity, which is illustrated by significant reactivity to the N-terminal truncated peptide 
FWSFGSEDGGG and the C-terminal truncated GSGFWSFGSE (Figure 2 a,b). No reactivity was 
found to the further truncated peptides (WSFGSEDGGG and GSGFWSFGS). Based on these 
findings, the minimum functional epitope of the mAb was identified as the aa sequence 
8FWSFGSE14.  
For the pAb, which recognized two continuous epitopes, notable antibody reactivity was found 
to the N-terminal truncated peptide TLEDNEERMSRLSKV and the C-terminal truncated peptide 
PSLRTLED (Figure 2 c,d), although the antibody reactivity to the RTLEDNEERMSRLSKV 
containing an N-terminal Arg was higher. Only truncated peptides containing the aas TLED reacted 
with the pAb, indicating that the TLED motif constitutes a central part of the epitope.  
Screening of GAD65 pAb reactivity to truncated analogues of peptide 55 
(GTTMVSYQPLGDKVNFFRMV), illustrated that the N-terminal truncated peptide LGDKVNFF 
and the C-terminal truncated peptide MVSYQPLGDKV were the shortest peptides to be recognized 
(Figure 2 e,f) although the peptide with a N-terminal Pro obtained a higher reactivity compared to 
Figure 1. Reactivity of antibodies to GAD65 peptides analysed by modified enzyme-linked
immunosorb nt ass y using resin-bound peptides. (a) Reactivity of the mAb GAD65 to peptides 1–3.
Resin without peptides was used for background determination and subtracted. Peptide 1: aa 1–20,
peptide 2: aa 10–30, peptide 3: aa 20–40. Peptide 3 was used as control peptide; (b) reactivity of the
pAb GAD65 to overlapping 20mer peptides covering aas 353–585. Resin without peptides was used for
background determination and subtracted; (c) reactivity of irrelevant antibody to overlapping peptides
covering aas 353–585.
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Figure 1b illustrates the reactivity of the pAb to overlapping peptides covering the aas 353–585.
Distinct reactivity was found to peptides 51 (aa 501–520, HTNVCFWYIPPSLRTLEDNE) and 52 (aa
511–530, PSLRTLEDNEERMSRLSKVA), indicating that the epitope is found in the aas 511–520,
PSLRTLEDNE. Reactivity was observed to peptides 38, 41, 49, 55 and 57 as well. However,
antibody reactivity to peptides 38, 41, 49 and 57 was ascribed to nonspecific reactivity, as a control
antibody of irrelevant specificity, reacted with these peptides as well (Figure 1c). Based on these
findings, peptide 52 (PSLRTLEDNEERMSRLSKVA) and 55 (GTTMVSYQPLGDKVNFFRMV) were
selected for further analyses.
2.2. Screening of N-Terminally and C-Terminally Truncated Peptides
To identify the terminal epitope borders of the GAD antibodies, N- and C-terminal
truncated resin-bound peptides were screened for antibody reactivity by modified
ELISA. Peptides 1 (MASPGSGFWSFGSEDGSGDS), 52 (PSLRTLEDNEERMSRLSKVA) and 55
(GTTMVSYQPLGDKVNFFRMV) were used as templates for the generation of truncated peptides.
Figure 2 represents GAD65 antibody reactivity to the terminally truncated peptides. For the mAb,
the N-terminal aa Phe (aa 8) and the C-terminal aa Glu (aa 14) were essential for antibody reactivity,
which is illustrated by significant reactivity to the N-terminal truncated peptide FWSFGSEDGGG and
the C-terminal truncated GSGFWSFGSE (Figure 2a,b). No reactivity was found to the further truncated
peptides (WSFGSEDGGG and GSGFWSFGS). Based on these findings, the minimum functional epitope
of the mAb was identified as the aa sequence 8FWSFGSE14.
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MVSYQPLGDKVN was low. Peptides with further truncated residues were not recognized by the 
pAb. Based on these findings, the aas to react significantly with the pAb were identified as 515TLED518 
and 550LGDKV554.  
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Figure 2. Reactivity of GAD65 antibodies to N- and C-terminally truncated peptides. (a) reactivity of 
the mAb GAD65 to N-terminally truncated peptides. Peptide 1 (MASPGSGFWSFGSEDGSGDS) was 
used as positive control; (b) reactivity of the mAb GAD65 to C-terminally truncated peptides. 
Peptide 1 was used as positive control; (c) reactivity of the pAb GAD65 to N-terminally truncated 
peptides of epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was used as positive control; (d) 
reactivity of the pAb GAD65 to C-terminally truncated peptides of epitope 1. Peptide 52 was used as 
positive control; (e) reactivity of the pAb GAD65 to N-terminally truncated peptides of epitope 2. 
Figure 2. Reactivity of GAD65 antibodies to N- and C-terminally truncated peptides. (a) reactivity of
the mAb GAD65 to N-terminally truncated peptides. Peptide 1 (MASPGSGFWSFGSEDGSGDS) was
used as positive control; (b) reactivity of the mAb GAD65 to C-terminally truncated peptides. Peptide
1 was used as positive control; (c) reactivity of the pAb GAD65 to N-terminally truncated peptides
of epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was used as positive control; (d) reactivity
of the pAb GAD65 to C-terminally truncated peptides of epitope 1. Peptide 52 was used as positive
control; (e) reactivity of the pAb GAD65 to N-terminally truncated peptides of epitope 2. Peptide
55 (GTTMVSYQPLGDKVNFFRMV) was used as positive control; (f) reactivity of the pAb GAD65 to
C-terminally truncated peptides of epitope 2. Peptide 55 was used as positive control.
For the pAb, which recognized two continuous epitopes, notable antibody reactivity was found
to the N-terminal truncated peptide TLEDNEERMSRLSKV and the C-terminal truncated peptide
PSLRTLED (Figure 2c,d), although the antibody reactivity to the RTLEDNEERMSRLSKV containing
Figure 2. Cont.
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Figure 2. Reactivity of GAD65 antibodies to N- and C-terminally truncated peptides. (a) reactivity of 
the mAb GAD65 to N-terminally truncated peptides. Peptide 1 (MASPGSGFWSFGSEDGSGDS) was 
used as positive control; (b) reactivity of the mAb GAD65 to C-terminally truncated peptides. 
Peptide 1 was used as positive control; (c) reactivity of the pAb GAD65 to N-terminally truncated 
peptides of epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was used as positive control; (d) 
reactivity of the pAb GAD65 to C-terminally truncated peptides of epitope 1. Peptide 52 was used as 
positive control; (e) reactivity of the pAb GAD65 to N-terminally truncated peptides of epitope 2. 
Figure 2. Reactivity of GAD65 antibodies to N- and C-terminally truncated peptides. (a) reactivity of
the mAb GAD65 to N-terminally truncated peptides. Peptide 1 (MASPGSGFWSFGSEDGSGDS) was
used as positive control; (b) reactivity of the mAb GAD65 to C-terminally truncated peptides. Peptide
1 was used as positive control; (c) reactivity of the pAb GAD65 to N-terminally truncated peptides
of epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was used as positive control; (d) reactivity
of the pAb GAD65 to C-terminally truncated peptides of epitope 1. Peptide 52 was used as positive
control; (e) reactivity of the pAb GAD65 to N-terminally truncated peptides of epitope 2. Peptide
55 (GTTMVSYQPLGDKVNFFRMV) was used as positive control; (f) reactivity of the pAb GAD65 to
C-terminally truncated peptides of epitope 2. Peptide 55 was used as positive control.
For the pAb, which recognized two continuous epitopes, notable antibody reactivity was found
to the N-terminal truncated peptide TLEDNEERMSRLSKV and the C-terminal truncated peptide
PSLRTLED (Figure 2c,d), although the antibody reactivity to the RTLEDNEERMSRLSKV containing
Figure 2. Reactivity of GAD65 antibodies to N- and C-terminally truncated peptides. (a) reactivity of
the mAb GAD65 to N-terminally truncated peptides. Peptide 1 (MASPGSGF SF SE S S) as
used as positive control; (b) reactivity of the mAb GAD65 to -ter i all truncated peptides. Peptide 1
was used as pos tive control; (c) re ti t e pAb GAD65 to N-terminally truncated pe tides of
epitope 1. Peptide 52 ( SRLSKVA) was used as positive control; (d) reactivi y of
the pAb GAD65 to C-termina ly truncate . s sitive
c ntrol; ( ) reactivity of the pAb GAD65 to N-ter i ll t cated peptides of epitope 2. Peptide 55
(G TMVSYQPLGDK FF ) as se as ositi e co trol; (f) reacti ity of t e b 65 to
C-terminally truncated peptides of epitope 2. Peptide 55 was used as positive control.
For the pAb, which recognized two continuous epitopes, notable antibody reactivity was found
to the N-terminal truncated peptide TLEDNEERMSRLSKV and the C-terminal truncated peptide
PSLRTLED (Figure 2c,d), although the antibody reactivity to the RTLEDNEERMSRLSKV containing
an N-terminal Arg was higher. Only truncated peptides containing the aas TLED reacted with the
pAb, indicating that the TLED motif constitutes a central part of the epitope.
Screening of GAD65 pAb reactivity to truncated analogues of peptide 55
(GTTMVSYQPLGDKVNFFRMV), illustrated that the N-terminal truncated peptide LGDKVNFF
and the C-terminal truncated peptide MVSYQPLGDKV were the shortest peptides to be recognized
(Figure 2e,f) although the peptide with a N-terminal Pro obtained a higher reactivity compared
to the LGDKVNFF peptide. Further antibody reactivity to the peptides MVSYQPLGDKV and
MVSYQPLGDKVN was low. Peptides with further truncated residues were not recognized by the
pAb. Based on these findings, the aas to react significantly with the pAb were identified as 515TLED518
and 550LGDKV554.
2.3. Final Identification of Complete Epitopes
To determine the complete GAD65 epitopes, competitive inhibition assays were conducted using
relevant truncated peptide analogues.
Figure 3a depicts the reactivity of the mAb to the truncated peptides
FWSFGSE-GSGFWSFGSEDGSG. As seen, all of the truncated peptides inhibited reactivity
to the control peptide (PGSGFWSFGSEDGSGDSEN), confirming that the aa sequence 8FWSFGSE14
constitutes the complete epitope of the mAb.
When analyzing antibody reactivity of the pAb to the truncated peptides (TLED-SLRTLEDNEE),
containing the central TLED motif, it was observed that the four aas alone were not sufficient to inhibit
antibody reactivity to the control peptide (peptide 52) (Figure 3b). The peptide RTLED was the shortest
peptide, which inhibited antibody reactivity to the same level as the 10mer peptide (SLTREDNEE),
indicating that the aas 514RTLED518 constitutes the complete epitope 1 of the pAb.
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Figure 3. Verification of GAD65 antibody epitopes by competitive inhibition assay. (a) Reactivity of 
the mAb GAD65 to truncated peptides. The peptide PGSGFWSFGSEDGSGDSEN was used as a 
positive control, wells with no peptides added were used as negative control; (b) reactivity of the 
pAb GAD65 to epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was used as positive control, 
wells with no peptides added were used as negative control; (c) reactivity of the pAb GAD65 to 
epitope 2. Peptide 55 (TTMVSYQPLGDKVNFFRM) was used as positive control, wells with no 
peptides added were used as negative control. 
When analyzing antibody reactivity of the pAb to the truncated peptides 
(TLED-SLRTLEDNEE), containing the central TLED motif, it was observed that the four aas alone 
were not sufficient to inhibit antibody reactivity to the control peptide (peptide 52) (Figure 3b). The 
peptide RTLED was the shortest peptide, which inhibited antibody reactivity to the same level as the 
10mer peptide (SLTREDNEE), indicating that the aas 514RTLED518 constitutes the complete epitope 1 
of the pAb.  
Finally, the second continuous epitope of the pAb was determined using truncated peptides 
(PLGDKV-YQPLGDKVNFFR) (Figure 3C). As seen, the peptide PLGDKVN inhibited antibody 
reactivity by approximately 50%, whereas the remaining peptides PLGDKVNF-YQPLGDKVNFFR 
inhibited antibody reactivity similar to the control peptide (peptide 55), indicating that the aas 
549PLGDKVNF556 constitute the second complete continuous epitope of the pAb.  
2.4. Identification of Essential Amino Acids  
To determine the contribution of each aa in the identified epitopes to the specific antibody 
interaction, competitive inhibition assays were conducted using Ala-substituted peptides.  
Figure 4a illustrates the reactivity of the mAb to Ala-substituted peptides, using the peptide 
FWSFGSE as template. As seen, peptides containing Ala in position 1 and 2 did not inhibit antibody 
reactivity, illustrating that the aas in these positions (Phe, Trp) were essential for reactivity. Ser in 
position 6 was not essential for antibody reactivity, as the peptide containing Ala in this position 
inhibited antibody reactivity to the same level as the control. Antibody reactivity was inhibited by 
approximately 60% when aas in position 3, 4, 5 and 7 were substituted with Ala.  
Figure 3. Verification of GAD65 antibody epitopes by competitive inhibition assay. (a) Reactivity of the
mAb GAD65 to truncated peptides. The p tide PGSGFWSFGSEDGSGDSEN w s used as a positive
control, wells with no peptides added were used as negative control; (b) reactivity of the pAb GAD65
t epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was us d as positive control, wells with no
eptides added were used as negative control; (c) reactivity of the pAb GAD65 to epitope 2. Peptide 55
(TTMVSYQPLGDKVNFFRM) was used as positive control, wells with no peptides added were used as
negative control.
Finally, the second continuous epitope of the pAb was determined using truncated peptides
(PLGDKV-YQPLGDKVNFFR) (Figure 3c). As seen, the peptide PLGDKVN inhibited antibody reactivity
by approximately 50%, whereas the remaining peptides PLGDKVNF-YQPLGDKVNFFR inhibited
antibody reactivity similar to the control peptide (peptide 55), indicating that the aas 549PLGDKVNF556
constitute the second complete continuous epitope of the pAb.
2.4. Identification of Essential Amino Acids
To determin the contr b tion of each aa in the identifi d ep topes to the specific antibody
interaction, competitive inhibition assays were conducted using Ala-substituted peptides.
Figure 4 illustrates the reactivity of t mAb to Ala-substituted peptides, using the peptide
FWSFGSE as template. As seen, peptides contai ing Ala in position 1 and 2 di not inhibit antibody
reactivity, illustrati g that aas i these positi s (Phe, Trp) w re essential for reactivity. Ser in
position 6 was not essential for antibody reactivity, as the peptide containing Ala in this position
inhibited an body reac vity to the same level as the control. Antibody reactivity was inhibited by
approximately 60% when aas in position 3, 4, 5 and 7 were substituted with Ala.
Figure 4b illustrates the reactivity of the pAb to Ala analogues of the RTLED peptide. As seen,
Asp in position 5 and to some extent Thr and Leu in position 2 and 3, respectively, were essential for
antibody reactivity, as peptides containing Ala in these positions did not inhibit antibody reactivity
compared to the controls (RTLED and peptide 52). In contrast, the aas Arg and Glu were not essential
for antibody reactivity, as substitution of these did not influence antibody reactivity.
Figure 4c illustrates the reactivity of the pAb to Ala-substituted peptides using the peptide
PLGDKVNF as template. As seen, primarily the aa Leu in position 2 was essential for antibody
reactivity, as the peptide containing an Ala residue in this position did not inhibit antibody reactivity.
The motif GDK was to some degree essential for reactivity, as substitution of these aas, reduced antibody
reactivity. The remaining Ala-substituted peptides inhibited antibody reactivity to some degree
compared to the control (PLGDKVNF), indicating that they were not essential for a direct contact
through their side chains with the pAb [2].
Finally, functionality substituted peptides were screened for antibody reactivity, to determine
whether the specific aa contribution to the antibody–antigen interaction relates to side chain functionality
or the specific side chain. Various aa-substituted analogues were tested for antibody reactivity in
competitive immunoassays.
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Figure 4. Reactivity of GAD65 antibodies to substituted peptide analogues. (a) Reactivity of the mAb 
GAD65 to Ala-substituted peptides. The peptides FWSFGSE and PGSGFWSFGSEDGSGDSEN were 
used as positive controls, wells without peptide inhibitors were used as negative control; (b) 
reactivity of the pAb GAD65 to Ala-substituted peptides. The peptide RTLED and peptide 52 
(PSLRTLEDNEERMSRLSKVA) were used as positive controls, wells without peptide inhibitors 
were used as negative control; (c) reactivity of the pAb GAD65 to Ala-substituted peptides. The 
peptide PLGDKVNF were used as positive control, wells without peptide inhibitors were used as 
negative control; (d) reactivity of the mAb GAD65 to functionality-substituted peptides. The 
peptides FWSFGSE and PGSGFWSFGSEDGSGDSEN were used as positive controls, wells without 
peptide inhibitors were used as negative control. (e) reactivity of the pAb GAD65 to 
functionality-substituted peptides. The peptide RTLED and peptide 52 
(PSLRTLEDNEERMSRLSKVA) were used as positive controls, wells without peptide inhibitors 
were used as negative control; (f) reactivity of the pAb GAD65 to functionality-substituted peptides. 
The peptide PLGDKVNF was used as positive control, wells without peptide inhibitors were used as 
negative control. 
Figure 4b illustrates the reactivity of the pAb to Ala analogues of the RTLED peptide. As seen, 
Asp in position 5 and to some extent Thr and Leu in position 2 and 3, respectively, were essential for 
antibody reactivity, as peptides containing Ala in these positions did not inhibit antibody reactivity 
compared to the controls (RTLED and peptide 52). In contrast, the aas Arg and Glu were not 
essential for antibody reactivity, as substitution of these did not influence antibody reactivity.  
Figure 4c illustrates the reactivity of the pAb to Ala-substituted peptides using the peptide 
PLGDKVNF as template. As seen, primarily the aa Leu in position 2 was essential for antibody 
reactivity, as the peptide containing an Ala residue in this position did not inhibit antibody 
reactivity. The motif GDK was to some degree essential for reactivity, as substitution of these aas, 
reduced antibody reactivity. The remaining Ala-substituted peptides inhibited antibody reactivity to 
some degree compared to the control (PLGDKVNF), indicating that they were not essential for a 
direct contact through their side chains with the pAb [2].  
Finally, functionality substituted peptides were screened for antibody reactivity, to determine 
whether the specific aa contribution to the antibody–antigen interaction relates to side chain 
Figure 4. Reactivity of GAD65 antibodies to substituted peptide analogues. (a) Reactivity of the
mAb GAD65 to Ala-substituted peptides. The peptides FWSFGSE and PGSGFWSFGSEDGSGDSEN
were used as positive controls, wells without peptide inhibitors were used as negative control;
(b) reactivity of the pAb GAD65 to Ala-substituted peptides. The peptide RTLED and peptide 52
(PSLRTLEDNEERMSRLSKVA) were used as positive controls, wells without peptide inhibitors were
used as negative control; (c) reactivity of the pAb GAD65 to Ala-substituted peptides. The peptide
PLGDKVNF were used as positive control, wells without peptide inhibitors were used as negative
control; (d) reactivity of the mAb GAD65 to functionality-substituted peptides. The peptides FWSFGSE
and PGSGFWSFGSEDGSGDSEN were used as positive controls, wells without peptide inhibitors
were used as negative control. (e) reactivity of the pAb GAD65 to functionality-substituted peptides.
The peptide RTLED and peptide 52 (PSLRTLEDNEERMSRLSKVA) were used as positive controls,
wells without peptide inhibitors were used as negative control; (f) reactivity of the pAb GAD65 to
functionality-substituted peptides. The peptide PLGDKVNF was used as positive control, wells without
peptide inhibitors were used as negative control.
For the mAb, the aas in position 1 and 4 were essentia for reactivity, as pept de containing aas of
similar functio ality in these positions did not inhibit antibody reactivity. Only Ser in position 3 and 6
could be substituted with Thr without influencing antibody reactivity (Figure 4d). Peptides containing
substituted aas in the remaining positions inhibited antibody reactivity by approximately 60%.
Analysis of the antibody reactivity of the pAb to the RLTED epitope, revealed that only Asp
in position 5 could not be replaced with an aa of similar functionality without interfering with
antibody reactivity [Figure 4e]. The remaining aas in positions 1–4 were replaced with aas with similar
functionality and maintained the ability of the peptide to inhibit antibody reactivity. The same applies
to the PLGDKVNF epitope. Antibody reactivity was partly reduced when replacing Leu with Ile,
the remaining aas were replaced with aas of similar functionality without interfering with antibody
recognition (Figure 4f).
2.5. Epitope Structures
To identify the orientation of the identified epitopes, the crystal structure of GAD65 was examined
using RasWin software. Unfortunately, the N-terminal structure of GAD has not been crystalized,
thus no structure could be assigned to the mAb epitope. However, given that the epitope is located
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in the first 20 aas of the proteins, the epitope is most likely localized in a flexible region without any
ordered structure, which applies to the majority of terminal epitopes [1,34].
The epitopes of the pAb were verified by the crystal structure. Epitope 514RTLED518 (colored in
red) was found in a flexible region connecting an α-helix (green) and a β-strand (blue). Unfortunately,
the structure of aas 518–519 was not verified in the crystal structure. These aas are represented by red
(aa 518) and grey (aa 519) dots. 2 aas at this position are not likely to alter the complete protein structure.
Epitope 2 (549PLGDKVNF556) of the pAb is located in a flexible turn connecting two strands.
As seen, the essential Leu residues in the epitopes are accessible (Figure 5c,d).
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of the pAb GAD65 is colored in red. The structure of aas 518–519 was not verified in the crystal structure.
These aas are represented by red (aa 518) and grey (aa 519) dots. The epitope is located in a flexible
region connecting an α-helix (green) and a β-strand (blue); (b) The epitope 549PLGDKVNF556 of the
pAb GAD65 is colored in yellow. The epitope is located in a turn connecting two strands; (c) Location
of the potential important Leu (aa 516) residue in the first epitope of the pAb GAD65; (d) location of the
potentially important Leu (aa 550) residue in the second epitope of the pAb GAD65.
3. Discussion
The present study describes epitope characterization of antibodies to GAD65. The mAb recognized
a single epitope, whereas the pAb recognized two linear epitopes. It remains to be determined whether
the pAb recognized two linear epitopes due to the structural nature of the immunogen applied,
as it remains unknown, whether a native or non-native immunogen was used for immunization.
The mAb, originally generated to aas 4–22, recognized the aa sequence 8FWSFGSE14 (Figures 2 and 3).
Especially the aas Phe8 and Trp9 were essential for antibody reactivity, as peptides containing Ala in
these positions did not inhibit antibody reactivity and as the antibody did not recognize peptide 2
(FGSEDGSGDSENPGTARAWC), lacking these two aas. The specific side chain of Phe8 was essential
to the binding of the antibody, as it could not be replaced with Ala or an aa of similar functionality.
In contrast, Trp could not be replaced with Ala but to some degree with Phe, indicating that a large
hydrophobic aa in this position is sufficient to sustain antibody reactivity. The remaining aas could to
some degree be substituted with Ala and still inhibit antibody reactivity.
The pAb originally directed to aas 353–585, recognized 2 epitopes, the aas 514RTLED518 and
549PLGDKVNF556. For the RLTED epitope, the aas Thr and Leu inhibited antibody reactivity by
approximately 50% when inhibited with Ala, but not when substituted with aas of similar functionality,
indicating that these aas contribute to sustain a stable structure. Alternatively, may Leu contribute
with hydrophobic interactions, as replacement of Ala to some degree inhibited antibody reactivity,
whereas replacement with Ile did not influence antibody reactivity. This remains to be determined.
Only Asp appeared to interact directly through the side chain with the antibody, as substitution
with Ala reduced antibody reactivity. Asp could, however, to some degree be replaced with Glu,
indicating that a negatively charged aa in theory is sufficient to obtain antibody reactivity, whereas the
remaining aas most likely contribute to maintain a stable conformation. A similar reactivity pattern was
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observed for the PLGDKVNF epitope. The majority of the aas could be replaced with Ala or an aa of
similar functionality without interfering with antibody reactivity. Only Leu could not be replaced with
Ala without reducing antibody reactivity, whereas Leu could be replaced with Ile without interfering
with antibody reactivity.
As seen for both the mAb and the pAb, peptide backbone and specific aa interactions were
essential for antibody binding. These findings are in accordance to previous studies describing that
some epitopes have a significant dependency of specific aa side chains in the epitope, whereas other
epitopes only make direct contact through a single or two aa side chains [2,3,6,10,13,19]. The mAb
appeared to be more dependent on specific aa contributions than the pAb. Aas that do not interact
directly with the antibodies, although side chain interactions, may contribute to maintain a stable
peptide structure, alternatively by contributing with hydrogen bonds though backbone interactions,
this remains to be verified, preferably through x-ray crystallography. However, this is time consuming
and requires large amounts of peptides and antibody.
The fact that the mAb seemingly was more dependent on specific aas for antibody recognition,
may be explained by the nature of the antibodies. The mAb is more specific for a single epitope,
whereas the pAb is less specific for the individual epitope, due to heterogeneity. The pAb represents
a collection of antibodies that are directed to the complete fragment, aa 353–585. As a consequence,
the pAb has a high overall affinity due to the recognition of multiple epitopes. When analyzing
antibody reactivity to the two individual epitopes, the pAb was very tolerant to changes in the primary
structure of the epitopes. One explanation to this observation is that the affinity of the pAb to the two
epitopes is reduced, which was supported by prolonged developing times and reduced reactivity and
ultimately increased tolerance to aa changes. This remains to be verified, e.g., by SPR experiments.
As presented in this study, hydrophobic aas were essential for antibody reactivity. Originally,
it was emphasized that hydrophilic amino acids are important for antibody–antigen interactions,
which conform to that many epitopes are surface-oriented [1,4,14]. Several studies describe that epitopes
are enriched in charged and polar aas and depleted of aliphatic hydrophic aas [2–4,10,13,16,35–37].
Especially the hydrophobic/constrained aa Pro has been reported to be found in epitope structures, as
Pro often is represented in turn structures [13,15]. These findings are in accordance with computational
characterization of B-cell epitopes conducted by Kringelum and colleagues, which indicate that
epitopes often contain one or few hydrophobic aas in the center in combination with charged aas on
the edge, with hydrophobic aas close to the antibody, positively charged aas further away and finally
hydrophilic aas between the hydrophobic and charged aas [16]. Collectively, several interactions
are in play to generate a stable antibody–antigen interaction. Based on the respective approximate
binding energies for ionic interactions (–5 kcal/mol), hydrogen bonds (–4 kcal/mol) and hydrophobic
interactions (–0.03) [38], ionic interactions and hydrogen bonds appear to be the main contributors for
a stable antibody–antigen complex [2,3,6,10,13,19].
Structural analysis of the epitopes of the pAb revealed that the epitopes are located in flexible
structures, which is in accordance to the literature [1,10,13]. The secondary structure of epitopes has
been analyzed carefully, and has been reported to have a significantly lower portion of helices and
strands and more loops and flexible regions compared to the composition of secondary structural
elements of the entire antigen [1,14,39,40].
Antibody reactivity to the GAD67 isoform, with a sequence identity of approximately 74%,
was determined as well, but the GAD65 antibodies were specific for GAD65 (results not shown), as the
epitopes identified were not present in the GAD67 isoform. A similar study has been conducted
using the GAD67 isoform as well [2]. Here, two epitopes were identified in the N-terminal of GAD67,
to aa 14–23 and 91–99. Fine mapping of these revealed that antibody reactivity was related to amino
acid side-chain functionality in combination with non-contact aas, which most likely contribute to a
stable protein structure [2]. These findings conform to results described in this study, indicating that
antibodies to the two GAD isoforms may experience similar reactivity patterns. For the epitope
in the aa sequence 14–23, a hydrophilic Thr in combination with a charged Asp were essential for
Int. J. Mol. Sci. 2019, 20, 2909 10 of 13
antibody reactivity, whereas for the epitope composed of the aas 91–99, hydrophobic aas were central
for antibody reactivity [2]. These findings are in accordance to findings in this study, describing that
hydrophobic interactions are essential for antibody reactivity. Collectively, these GAD antibodies
appear to depend on a combination of specific interactions, rather than restricted to a single interaction.
Antibody reactivity to GAD65 epitopes has been very sparsely described, which only identify
potential antigenic regions rather than concrete epitope structures. This most likely relates to that
the majority of the immunodominant epitopes of GAD65 are discontinuous [1,16]. This study has
described antibody reactivity to continuous epitopes, which may aid in the process of identifying and
characterizing potential GAD65 epitopes in T1D.
4. Materials and Methods
4.1. Materials
Tentagel S NH2 resin was purchased from RAPP Polymere GmbH (Tübingen, Germany).
Alkaline phosphatase (AP)-conjugated anti-mouse IgG and para-nitrophenylphosphate (pNPP) were
purchased from Sigma Aldrich (Steinheim, Germany). Tris-Tween-NaCl (TTN) buffer (0.05 M Tris,
0.3 M NaCl, 1% Tween 20, pH 7.4), AP substrate buffer (1M diethanolamine, 0.5 mM MgCl2, pH 9.8),
carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, 0.001% phenolred, pH 9.6) were from Statens Serum
Institut (Hillerød, Denmark). Mouse GAD65 (clone no. 144) mAb was from GeneTex (immunogen:
aa 4–22 of human GAD65) and rabbit GAD65 (clone no. 2) pAb was from Origene (immunogen:
aa 353–585 of human GAD65). Overlapping peptides used for initial scanning and free peptides used
for final epitope identification were purchased from Schäfer-N (Lyngby, Denmark).
4.2. Peptides
The human GAD65 published sequence (Swiss-Prot: Q05329.1) was used to generate overlapping
20mer peptides, which covered the complete protein. Each peptide contained an overlap of 10 aas to the
next peptide. In total, 58 peptides were generated by 9-fluorenylmetyloxycarbonyl solid-phase peptide
synthesis. Peptides 1–3 were screened for reactivity to the mAb and peptides 36–58 were screened for
reactivity to the pAb. Peptide 2 (aa 11–30), 55 (aa 511–530) and 57 (aa 510–560) were used as templates
for generation of N-terminal and C-terminal truncated peptides. Ala- and functionality-substituted
peptides were generated using the aa sequences 8FWSFGSE14, 514RTLED518 and 549PLGDKVNF556
as templates. Each aa was systematically substituted with Ala or an aa of similar functionality.
All peptides are listed in Supplementary File.
4.3. Modified Enzyme-Linked Immunosorbent Assay
Resin-bound peptides were screened for reactivity as described elsewhere [7,10]. Briefly,
resin-bound peptides (100 µL) (1 mg/mL), diluted 1:30 in TTN, were added to a 96-well multiscreen
filterplate (Millipore, Copenhagen, Denmark) and rinsed with TTN buffer (250 µL/well) using a
multiscreen vacuum manifold. PAb (1:1000) and mAb (1 µg/mL) (100 µL) were diluted in TTN added
to the wells and incubated for 1 h at room temperature (RT) on a shaking table. Next, resins were rinsed
3 × 1 min as previously described and AP-conjugated anti-mouse IgG and anti-rabbit IgG (100 µL,
1 µg/mL) were added to the wells and incubated for 1 h at RT on a shaking table. Bound antibodies
were quantified using pNPP (1 mg/mL, 100 µL) diluted in AP substrate buffer. Finally, the buffer
was transferred to a Maxisorp microtitre plate (Nunc, Roskilde, Denmark) and the absorbance was
measured at 405 nm, with background subtraction at 650 nm, on a Thermomax microtitre plate reader
(Molecular Devices, Menlo Park, CA, USA).
4.4. Competitive Inhibition Assay
Maxisorp microtitre plates were coated with peptides 1, 52 and 55 (1 µg/mL) in carbonate buffer
for 2 h at RT. In another plate, peptide analogues (1 mg/mL) and GAD65 antibody (mAb 1 µg/mL,
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pAb, 1:1000 dilution) were incubated for 1 h at RT. Next, the peptide-antibody samples were added to
the coated microtitre wells and incubated for 1 h at RT on a shaking table, whereafter the wells were
rinsed with TTN. Following this, the wells were incubated with AP-conjugated anti-mouse IgG or
anti-rabbit IgG (100 µL, 1 µg/mL) for 1 h at RT on a shaking table. Bound antibodies were quantified
using pNPP (1 mg/mL, 100 µL) diluted in AP substrate buffer and the absorbance was measured at
405 nm, with background subtraction at 650 nm, on a Thermomax microtitre plate reader (Molecular
Devices, Menlo Park, CA, USA).
4.5. Structural Analysis of GAD65 Epitopes
The software Raswin Cn3D 4.1 was used to identify the location and secondary structure of the
identified mAb and pAb epitopes in human GAD65 (PDB ID: 2OKK).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/12/
2909/s1.
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Abbreviations
aa Amino acid
AP Alkaline phosphatase
ELISA Enzyme-linked immunosorbent assay
GABA Γ-aminobutyric acid
GAD Glutamate decarboxylase
PLP Pyridoxal phosphate
pNPP Para-nitrophenylphosphate
T1D Type 1 diabetes
TTN Tris-Tween-NaCl
SPS Stiff-person syndrome
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